Roberto Mignone decreased its stake in Atara Biotherapeutics Inc (ATRA) by 2.28% based on its latest 2018Q1 regulatory filing with the SEC. Bridger Management Llc sold 59,376 shares as the company’s stock rose 16.47% while stock markets declined. The hedge fund run by Roberto Mignone held 2.54 million shares of the health care company at the end of 2018Q1, valued at $99.03 million, down from 2.60M at the end of the previous reported quarter. Bridger Management Llc who had been investing in Atara Biotherapeutics Inc for a number of months, seems to be less bullish one the $1.98B market cap company. The stock increased 2.62% or $1.15 during the last trading session, reaching $45.1. About 498,834 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 248.61% since June 13, 2017 and is uptrending. It has outperformed by 236.04% the S&P500.
United Services Automobile Association decreased its stake in Davita Inc (DVA) by 41.02% based on its latest 2018Q1 regulatory filing with the SEC. United Services Automobile Association sold 32,849 shares as the company’s stock declined 7.63% with the market. The institutional investor held 47,228 shares of the hospital and nursing management company at the end of 2018Q1, valued at $3.11M, down from 80,077 at the end of the previous reported quarter. United Services Automobile Association who had been investing in Davita Inc for a number of months, seems to be less bullish one the $12.38 billion market cap company. The stock decreased 1.10% or $0.79 during the last trading session, reaching $70.97. About 1.45M shares traded. DaVita Inc. (NYSE:DVA) has risen 2.44% since June 13, 2017 and is uptrending. It has underperformed by 10.13% the S&P500. Some Historical DVA News: 11/05/2018 – BERKSHIRE HATHAWAY INC REPORTS 22.1 PCT STAKE IN DAVITA INC AS OF MAY 3, 2018 – SEC FILING; 13/03/2018 – DaVita Inc. Continues to Expect Pending Transaction Will Close in 2018; 02/05/2018 – DaVita’s Sustainability Efforts Rewarded by Department of Energy; 09/04/2018 – National Kidney Foundation features DaVita Clinical Research Results at 2018 Spring Clinical Meetings; 13/03/2018 – DaVita Inc.: Will Continue to Work ‘Diligently and Cooperatively’ with FTC on Revie; 23/04/2018 – DaVita Recognized as a LearningElite Company by Chief Learning Officer Magazine; 11/05/2018 – Moody’s Assigns Baa3 Ratings To Davita’s Senior Secured Term Loan Add-ons; 03/05/2018 – DaVita 1Q Cont Ops EPS $1.05
Analysts await DaVita Inc. (NYSE:DVA) to report earnings on August, 7. They expect $0.98 EPS, up 6.52% or $0.06 from last year’s $0.92 per share. DVA’s profit will be $171.01M for 18.10 P/E if the $0.98 EPS becomes a reality. After $1.05 actual EPS reported by DaVita Inc. for the previous quarter, Wall Street now forecasts -6.67% negative EPS growth.
Investors sentiment increased to 0.9 in Q1 2018. Its up 0.16, from 0.74 in 2017Q4. It is positive, as 35 investors sold DVA shares while 159 reduced holdings. 70 funds opened positions while 105 raised stakes. 145.68 million shares or 0.35% more from 145.16 million shares in 2017Q4 were reported. Alabama-based Retirement Of Alabama has invested 0.05% in DaVita Inc. (NYSE:DVA). Orbimed Advisors Lc holds 1.56M shares. Magnetar Limited Liability Corporation accumulated 10,087 shares or 0.02% of the stock. Berkshire Asset Mngmt Llc Pa reported 3,239 shares. Bridgewater Associate LP holds 0.14% or 223,124 shares in its portfolio. Wells Fargo & Mn reported 0.01% in DaVita Inc. (NYSE:DVA). Northstar Gp holds 0.38% in DaVita Inc. (NYSE:DVA) or 11,034 shares. Manufacturers Life Ins The owns 157,024 shares or 0.01% of their US portfolio. Dnb Asset As holds 0% in DaVita Inc. (NYSE:DVA) or 226,010 shares. 206,100 are owned by Quantitative Mgmt Ltd Liability. Aviva Public Ltd Liability holds 0.03% or 75,071 shares. Blackrock Incorporated owns 12.37 million shares for 0.04% of their portfolio. Jpmorgan Chase Com holds 0% or 316,526 shares in its portfolio. Bnp Paribas Arbitrage Sa stated it has 0% in DaVita Inc. (NYSE:DVA). Wellington Mngmt Gru Ltd Liability Partnership holds 0% or 64,599 shares.
Among 13 analysts covering DaVita (NYSE:DVA), 5 have Buy rating, 3 Sell and 5 Hold. Therefore 38% are positive. DaVita had 41 analyst reports since August 6, 2015 according to SRatingsIntel. On Monday, November 13 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. Raymond James upgraded DaVita Inc. (NYSE:DVA) on Thursday, December 7 to “Strong Buy” rating. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, November 8 report. On Monday, December 11 the stock rating was upgraded by Citigroup to “Buy”. The firm has “Buy” rating given on Thursday, January 11 by Robert W. Baird. Bank of America upgraded DaVita Inc. (NYSE:DVA) rating on Thursday, January 4. Bank of America has “Buy” rating and $85 target. The stock has “Hold” rating by SunTrust on Tuesday, April 17. The firm earned “Underweight” rating on Monday, October 9 by JP Morgan. SunTrust maintained it with “Hold” rating and $57.0 target in Friday, October 13 report. The rating was maintained by RBC Capital Markets on Wednesday, November 4 with “Sector Perform”.
Another recent and important DaVita Inc. (NYSE:DVA) news was published by Globenewswire.com which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within PPL, The Travelers Companies, Xilinx, United …” on June 12, 2018.
United Services Automobile Association, which manages about $37.14 billion US Long portfolio, upped its stake in Baker Hughes A Ge Co by 17,824 shares to 167,364 shares, valued at $4.65 million in 2018Q1, according to the filing. It also increased its holding in Nabriva Therapeutics Plc by 243,000 shares in the quarter, for a total of 354,763 shares, and has risen its stake in Yum! Brands Inc (NYSE:YUM).
Since January 16, 2018, it had 0 buys, and 4 insider sales for $493,996 activity. ROPER WILLIAM L also sold $102,677 worth of DaVita Inc. (NYSE:DVA) on Tuesday, May 22. $86,918 worth of DaVita Inc. (NYSE:DVA) was sold by Arway Pamela M. $22,393 worth of stock was sold by BERG CHARLES on Monday, May 14.
Since January 10, 2018, it had 0 insider buys, and 29 selling transactions for $19.73 million activity. $1.68M worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Ciechanover Isaac E.. Clark Mitchall G. also sold $214,026 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. 1,183 shares valued at $55,010 were sold by Gallagher Carol Giltner on Thursday, February 15. Fust Matthew K sold 12,286 shares worth $535,301. $464,210 worth of stock was sold by Turner Heather D on Friday, February 9. 25,775 shares were sold by Haqq Christopher, worth $1.17 million.
Among 10 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Atara Biotherapeutics had 28 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Market Perform” rating by JMP Securities on Wednesday, February 28. The rating was reinitiated by Jefferies on Monday, October 24 with “Buy”. The firm earned “Buy” rating on Friday, April 6 by William Blair. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Sell” rating by Citigroup on Monday, June 11. J.P. Morgan initiated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Tuesday, April 10. J.P. Morgan has “Buy” rating and $5600 target. On Friday, September 25 the stock rating was initiated by JMP Securities with “Mkt Perform”. Jefferies reinitiated the shares of ATRA in report on Thursday, June 22 with “Buy” rating. As per Monday, August 22, the company rating was maintained by Citigroup. Jefferies maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, March 5 with “Buy” rating. JMP Securities maintained it with “Market Outperform” rating and $40 target in Tuesday, December 15 report.
Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on August, 6. They expect $-0.97 EPS, down 3.19% or $0.03 from last year’s $-0.94 per share. After $-1.05 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -7.62% EPS growth.
Investors sentiment increased to 3.86 in Q1 2018. Its up 2.44, from 1.42 in 2017Q4. It is positive, as 9 investors sold ATRA shares while 12 reduced holdings. 38 funds opened positions while 43 raised stakes. 83.11 million shares or 198.24% more from 27.87 million shares in 2017Q4 were reported. Tiaa Cref Invest Mngmt Ltd Liability Co, New York-based fund reported 73,832 shares. California State Teachers Retirement Systems holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 50,110 shares. Alliancebernstein LP has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 28,840 shares. Sg Americas Securities Ltd Liability Co holds 0% or 2,749 shares in its portfolio. Commercial Bank Of Mellon has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Fmr Ltd Co has 6.20M shares. 297,746 were reported by Putnam Invs Lc. Pnc Fincl Serv Gru Inc holds 34 shares. Jpmorgan Chase & invested in 6,625 shares. 24,505 are owned by Manufacturers Life The. 10,543 were accumulated by Harbourvest Prns Ltd Liability Company. Barclays Public Ltd accumulated 8,598 shares. 391,436 were accumulated by Northern Tru. Citadel Advisors Limited Company invested in 0% or 20,475 shares. Driehaus Mgmt Ltd accumulated 142,827 shares.
More notable recent Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news were published by: Globenewswire.com which released: “Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences” on May 29, 2018, also Seekingalpha.com with their article: “Atara Biotherapeutics: A Gift That Keeps On Giving” published on May 17, 2018, Globenewswire.com published: “Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer” on June 07, 2018. More interesting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were released by: Seekingalpha.com and their article: “Atara Biotherapeutics: What Q1 2018 Earnings Foretell?” published on May 18, 2018 as well as Wallstreetpr.com‘s news article titled: “Excitement Builds in the High-Growth High-Momentum Biotech Space (CRSP,NTRB,ATRA)” with publication date: June 13, 2018.